Cargando…
PUS1 is a novel biomarker for evaluating malignancy of human renal cell carcinoma
Renal cell carcinoma (RCC) is one of the most common malignancies. Despite the rapid development of the oncology research and surgical treatment, the prognosis of RCC has not significantly improved. Thus, exploration of the pathological molecular mechanism and development of new therapeutic targets...
Autores principales: | Li, Lin, Zhu, Chongying, Xu, Shouying, Xu, Qiang, Xu, Da, Gan, Sishun, Cui, Xingang, Tang, Chao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292901/ https://www.ncbi.nlm.nih.gov/pubmed/37315299 http://dx.doi.org/10.18632/aging.204799 |
Ejemplares similares
-
PUS1 is a novel biomarker for predicting poor outcomes and triple-negative status in breast cancer
por: Fang, Zheng, et al.
Publicado: (2022) -
Integration of intratumoral RASSF10 expression and tumor-associated macrophages into the established clinical indicators better predicts the prognosis of clear cell renal cell carcinoma patients
por: Wang, Chao, et al.
Publicado: (2020) -
Frizzled 8 promotes the cell proliferation and metastasis of renal cell carcinoma
por: Yang, Qiwei, et al.
Publicado: (2017) -
Pus Inoculations
por: Nesfield, V.
Publicado: (1914) -
Origin of Pus
por: Patrick, J. B.
Publicado: (1892)